# American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2022

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2022-08-08
- Accepted by EDGAR: Aug 8, 2022, 16:07 ET
- Period: 2022-06-30
- Accession: 0001564590-22-028438
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000156459022028438/avd-10q_20220630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000156459022028438/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $148.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $297.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-04-01 to 2022-06-30 | $88.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2022-01-01 to 2022-06-30 | $176.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2022-04-01 to 2022-06-30 | $59.8m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2022-01-01 to 2022-06-30 | $121.0m | us-gaap:GrossProfit |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | $10.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | $25.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-04-01 to 2022-06-30 | $772.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2022-01-01 to 2022-06-30 | $1.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-04-01 to 2022-06-30 | $2.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-01-01 to 2022-06-30 | $7.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | $6.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | $16.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.23 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.55 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.23 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.57 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 30,225,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 30,289,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | −$27.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 6 months, 2022-01-01 to 2022-06-30 | $1.3m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2022-01-01 to 2022-06-30 | $6.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-06-30 | $22.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $400.1m | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $743.6m | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $212.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $358.8m | us-gaap:Liabilities |
| Long-term debt | at 2022-06-30 | $100.8m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2022-06-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2022-06-30 | $384.8m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 36,510 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Annual Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 3., Quantitative and Qualitative Disclosures about Market Risk, and Part II, Item 1A., Risk Factors, in this Quarterly Report on Form 10-Q.

### MANAGEMENT OVERVIEW

### Overview of the Company’s Performance

During the second quarter of 2022, the agriculture industry proceeded further into the second year of an upcycle, following a multi-year downcycle. While subject to intra-day fluctuations, commodity prices for row crops, which are largely driven by global conditions, were consistently strong. Consequently, the domestic farm economy showed continued resiliency. Geopolitical conditions, particularly the prolonged invasion of Ukraine, provided further price support for corn (and, consequently, soybeans), wheat and sunflower oil, as well as fertilizers. With improved supply chain conditions and a stronger U.S. dollar, domestic companies experienced enhanced buying power. Despite the advent of the BA5 variant, in the face of higher vaccination rates, the COVID-19 pandemic has shifted into an endemic in most regions. Amidst these factors and following on the heels of an extremely strong first quarter, the Company’s overall operating results for the second quarter of 2022 improved in most respects, as compared with those of the same period of 2021. Led by the strong sales growth of our international business, consolidated net sales increased by 10% (to end at $148,084 as compared to $134,610) and net income increased by 33% (to $6,830 from $5,144).

On a consolidated basis, domestic sales rose 1% and international sales increased 26%, resulting in an overall net sales improvement of 10%. In comparison, cost of sales increased by 7% or $5,834. This lower comparative increase was a result of higher selling prices and a favorable mix of higher-margin products in the second quarter of 2022, as compared to the same period of the prior year. Cost of sales were 60% of sales in the second quarter of 2022, as compared to 61% for the same period of 2021. These factors, taken together, yielded a 15% increase in gross profit (to $59,779 from $52,139 in the comparable quarter of 2021), while overall gross margin percent improved to 40% from 39% quarter-over-quarter.

Operating expenses increased to 33% of net sales (or $48,966), as compared to 32% (or $43,080) in the same period of the prior year primarily due to legal and other expenses amounting to $1,785 relating to proxy defense activity in the reporting period. Absent those expenses, our operating expenses would have been at 32%, in line with the same period of the prior year.

Operating income for the period increased by 21% (to $10,813 from $8,971), driven by the overall sales increase, higher selling prices and improved factory utilization. Interest expense was 24% lower than the same period of 2021, driven by lower average levels of debt, which was aided by a second consecutive year of strong customer participation in early pay programs. These factors yielded net income for the period of $6,830, a 33% increase over compared to $5,144 in the second quarter of 2021. Details on our financial performance are set forth below.

### RESULTS OF OPERATIONS

### Quarter Ended June 30, 2022 and 2021:

| Net sales: | 2022 | 2021 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| U.S. crop | $63,195 | $62,575 | $620 | 1% |
| U.S. non-crop | 21,316 | 21,488 | (172) | -1% |
| Total U.S. | 84,511 | 84,063 | 448 | 1% |
| International | 63,573 | 50,547 | 13,026 | 26% |
| Total net sales: | $148,084 | $134,610 | $13,474 | 10% |
| Cost of sales: |  |  |  |  |
| U.S. crop | $33,442 | $35,770 | $(2,328) | -7% |
| U.S. non-crop | 11,267 | 11,706 | (439) | -4% |
| Total U.S. | 44,709 | 47,476 | (2,767) | -6% |
| International | 43,596 | 34,995 | 8,601 | 25% |
| Total cost of sales: | $88,305 | $82,471 | $5,834 | 7% |
| Gross profit: |  |  |  |  |
| U.S. crop | $29,753 | $26,805 | $2,948 | 11% |
| U.S. non-crop | 10,049 | 9,782 | 267 | 3% |
| Total U.S. | 39,802 | 36,587 | 3,215 | 9% |
| International | 19,977 | 15,552 | 4,425 | 28% |
| Total gross profit | $59,779 | $52,139 | $7,640 | 15% |
| Gross margin: |  |  |  |  |
| U.S. crop | 47% | 43% |  |  |
| U.S. non-crop | 47% | 46% |  |  |
| Total U.S. | 47% | 44% |  |  |
| International | 31% | 31% |  |  |
| Total gross margin | 40% | 39% |  |  |

Our **domestic crop business** recorded net sales that were 1% higher than those of the second quarter of 2021 ($63,195, as compared to $62,575). Led by Dacthal, Impact, Assure II and Envoke, offset to a degree by lower sales of our Classic and Python brands. The herbicide brands showed strong growth across all markets, as weed management planning has become instrumental in controlling resistant weeds in cotton, sugarcane, soybeans, corn and high value crops. Our lead brands in cotton generated positive growth during the quarter due, in the case of Bidrin, to increased early season pest pressure, and, in the case of Folex, to an anticipated early harvest season as hot dry weather pushes cotton maturity ahead of seasonal norms. Partially offsetting these gains, sales of Thimet, Aztec and Counter were down in the quarter following unusually high demand in the first quarter. Further, lingering drought conditions in our Western and Southwestern markets adversely impacted our soil fumigant sales, as water allocations have limited annual crop production in those regions. Drier conditions also suppressed sales of Dibrom during the period.

Cost of sales within the domestic crop business decreased by 7% (from $35,770 in 2021 to $33,442 in 2022) primarily as a result of selling more, higher-margin products. As the result of better pricing and favorable factory performance, domestic crop generated an 11% increase in gross profit (from $26,805 in the first quarter of 2021 to $29,753 this year) on a 1% increase in sales.

Our **domestic non-crop business** posted nearly flat net sales in the second quarter of 2022, as compared to the same period in the prior year (down 1% to $21,316 from $21,488 in 2021). In the quarter, relief from pandemic restrictions – primarily return to in-person school and work – has had a two-pronged effect on our non-crop business. On the one hand, the demand for nursery, ornamental and consumer products for the home declined, as people spent less time in their homes. On the other hand, we saw an uptick in demand for goods that we supply to professional applicators and landscapers, as homeowners shifted from do-it-yourself to using professional services. In addition, we enjoyed higher sales of our pharmaceutical products from GemChem, while seeing an offsetting softness in the turf supply market, as golfing activity declined.

Cost of sales within the domestic non-crop business declined by 4% in the second quarter of 2022, as compared to the same period in the prior year (from $11,706 in 2021 to $11,267 in 2022), primarily resulting from improved factory performance and associated overhead cost recovery. Gross profit for domestic non-crop increased by 3% (from $9,782 in 2021 to $10,049 in 2022).

Net sales of our **international businesses** rose by 26% during the period ($63,573 in 2022 vs. $50,547 in 2021) and constituted 43% of our consolidated sales. These businesses benefited from sales increases in soil fumigants, foliar insecticides, soil insecticides and fungicides across many regions. Our Central American business enjoyed increased demand in the pineapple, banana and citrus markets, including stronger sales of our Greenplants micronutrient solutions. In Mexico, despite drought conditions in the north, our Mexico business experienced good performance from at-plant fumigants and herbicides on high-value crops. Our Brazilian business benefited from increased sales of Counter on corn, while our Australian operations posted stronger sales in light of increased rainfall, heavy demand for molluscicides as well as insecticide products for use on canola, winter wheat and pulse.

Cost of sales in our international business increased by 25% (from $34,995 in 2021 to $43,596 in 2022), on sales that increased by 26% and was impacted by cost increases (including logistics and freight) of the third-party products that we distribute. Gross profit for the international businesses increased by 28% (to $19,977 in 2022 from $15,552 in 2021).

On a **consolidated basis,** gross profit for the second quarter of 2022 increased by 15% (from $52,139 in 2021 to $59,779 in 2022). Overall gross margin percentage ended at 40% in the second quarter of 2022, as compared to 39% in the second quarter of the prior year. The primary driver for this increase was higher selling prices coupled with improved factory performance, partially offset by inflation on raw materials and logistics and, for our international businesses, higher purchases costs related to increases in the US Dollar.

Operating expenses increased by $5,886 to $48,966 for the three-month period ended June 30, 2022, as compared to the same period in 2021. The differences in operating expenses by department are as follows:

|  | 2022 | 2021 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $12,598 | $11,611 | $987 | 9% |
| General and administrative: |  |  |  |  |
| Other | 16,258 | 15,264 | 994 | 7% |
| Proxy contest activities | 1,785 | — | 1,785 | 100% |
| Research, product development and regulatory | 7,758 | 6,929 | 829 | 12% |
| Freight, delivery and warehousing | 10,567 | 9,276 | 1,291 | 14% |
| Subtotal | 48,966 | 43,080 | 5,886 | 14% |

- Selling expenses increased by $987 to end at $12,598 for the three-month period ended June 30, 2022, as compared with the same period of the prior year. This included increased costs associated with travel expenses (as the business resumed in-person interaction with customers), increased spending on advertising and promoting the Company’s products and the impact of movements in some key exchange rates.
- General and administrative, other expenses increased by $994 to end at $16,258 for the three-month period ended June 30, 2022, as compared to the same period of 2021. The main drivers were adverse impacts on the foreign currency exchange rates, and increased wages, travel expenses and other administrative costs in support of our growing business.
- The Company spent $1,785 in fees associated with our Proxy defense activities; there were no such fees in the comparative period of the prior year.
- Research, product development costs and regulatory expenses increased by $829 to end at $7,758 for the three-month period ended June 30, 2022, as compared to the same period of 2021. The main drivers were increased costs associated with our proprietary delivery systems, and our research and product development activities.
- Freight, delivery and warehousing costs for the three-month period ended June 30, 2022 were $10,567 or 7.1% of sales as compared to $9,276 or 6.9% of sales for the same period in 2021. This change was primarily driven by increased overall sales volume, the associated delivery destinations during the period, and the expenses incurred related to supply chain issues and inflation in logistics costs.

On April 1, 2020, the Company made a strategic investment in Clean Seed Inc., in the amount of $1,190. The Company recorded negative fair value adjustments in the amount of $486 and $296 for the three months ended June 30, 2022 and 2021, respectively.

Interest costs net of capitalized interest were $772 in the three-month period ended June 30, 2022, as compared to $1,013 in the same period of 2021. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Three months ended June 30, 2022 Average Debt | Interest Expense | Interest Rate | Three months ended June 30, 2021 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $124,184 | $745 | 2.4% | $163,140 | $984 | 2.4% |
| Amortization of deferred loan fees | — | 69 | — | — | 80 | — |
| Amortization of other deferred liabilities | — | 11 | — | — | (25) | — |
| Other interest expense | — | 12 | — | — | 39 | — |
| Subtotal | 124,184 | 837 | 2.7% | 163,140 | 1,078 | 2.6% |
| Capitalized interest | — | (65) | — | — | (65) | — |
| Total | $124,184 | $772 | 2.5% | $163,140 | $1,013 | 2.5% |

The Company’s average overall debt for the three-month period ended June 30, 2022 was $124,184, as compared to $163,140 for the three-month period ended June 30, 2021. Our borrowings in the three-month period ended June 30, 2022, were lower mainly due to cash generated over the last 12 months used to pay down debt, partially offset by the acquisition activity over the same period and growth in working capital in support of business growth. As can be seen from the table above, the effective bank interest rate on our revolving line of credit was 2.4% at each of the three-month period ended June 30, 2022 and 2021.

Income tax expense increased by $280 to $2,725 for the three-month period ended June 30, 2022, as compared to $2,445 for the comparable period in 2021. The effective tax rates for the three-month period ended June 30, 2022, and 2021, were 28.5% and 31.9%, respectively. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The decrease in effective tax rate was primarily driven by the mix of our domestic and international income and benefit from the tax impact of the vesting of certain stock grants.

Our net income for the three-month period ended June 30, 2022, was $6,830 or $0.23 per basic and diluted share, as compared to $5,144 or $0.17 per basic and diluted share in the same quarter of 2021.

### Six Months Ended June 30, 2022 and 2021:

### Overview of the Company’s Performance

Within the global agricultural industry, the first six months of 2022 were a prolongation of the upcycle that began in 2021. Commodity prices remained high, driven in part by the Russian invasion of Ukraine, which has served to reduce exports from both Russia and Ukraine, of corn, wheat, sunflower oil and fertilizer inputs into the global market, and a stronger farm economy in the U.S. Following extraordinary activity in the first quarter, domestic distribution within our industry slowed procurement modestly during the second quarter. Our international businesses, for the most part, enjoyed strong market conditions in nearly all regions during the first half of the year. All told, the Company’s overall operating results for the first six months of 2022 improved considerably over those of the same period of 2021.

On a consolidated basis, with domestic sales up 19% and international sales up by 18%, overall net sales increased by 19% (to $297,519 from $250,765). Cost of sales were up 15% on an absolute basis but decreased as a percent of net sales to 59% from 61%. Factory performance improved during the first half of 2022, as compared to that of 2021. These factors, taken together, yielded an increase in gross profit, which was up $23,702 or 24% (to $120,972 from $97,270) and improved to 41% of net sales, up from 39% during the first half of 2021. In the first half of 2022, while operating expenses rose on an absolute basis by 13%, these costs declined as a percent of net sales to 32% from 34% for the same period of the prior year.

Interest expense declined by 40%, while income tax expense increased primarily as a result of stronger financial performance partially offset by a decrease in effective tax rate compared to the first half of the prior year (at 30.1% in 2022 and 31.4% in the prior year). Overall, the Company’s net income for the period increased by a factor of two, ending at $16,765, as compared to $8,215 during the first half of the prior year. Details on our financial performance are set forth below.

### RESULTS OF OPERATIONS

### Six months ended June 30, 2022, and 2021

| Net sales: | 2022 | 2021 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| U.S. crop | $151,388 | $117,330 | $34,058 | 29% |
| U.S. non-crop | 34,712 | 38,941 | (4,229) | -11% |
| Total U.S. | 186,100 | 156,271 | 29,829 | 19% |
| International | 111,419 | 94,494 | 16,925 | 18% |
| Total net sales: | $297,519 | $250,765 | $46,754 | 19% |
| Cost of sales: |  |  |  |  |
| U.S. crop | $81,290 | $69,254 | $12,036 | 17% |
| U.S. non-crop | 18,698 | 19,776 | (1,078) | -5% |
| Total U.S. | 99,988 | 89,030 | 10,958 | 12% |
| International | 76,559 | 64,465 | 12,094 | 19% |
| Total cost of sales: | $176,547 | $153,495 | $23,052 | 15% |
| Gross profit: |  |  |  |  |
| U.S. crop | $70,098 | $48,076 | $22,022 | 46% |
| U.S. non-crop | 16,014 | 19,165 | (3,151) | -16% |
| Total U.S. | 86,112 | 67,241 | 18,871 | 28% |
| International | 34,860 | 30,029 | 4,831 | 16% |
| Total gross profit | $120,972 | $97,270 | $23,702 | 24% |
| Gross margin: |  |  |  |  |
| U.S. crop | 46% | 41% |  |  |
| U.S. non-crop | 46% | 49% |  |  |
| Total U.S. | 46% | 43% |  |  |
| International | 31% | 32% |  |  |
| Total gross margin | 41% | 39% |  |  |

Our **domestic crop business** recorded net sales that were 29% above those of first half of 2021 (to $151,388 from $117,330) Assisted by consistently high commodity prices and a strong domestic farm economy, the Company experienced strong demand across all product categories. Further, with our domestic production capacity, we were able to meet demand in spite of international supply constraints. Our herbicide portfolio for use on corn, soybeans, cotton and sugar cane, and our granular soil insecticides both grew by approximately 60%. Foliar insecticides grew by 20% in the first half versus 2021. The only area of reduced demand was for soil fumigants, which experienced lower sales due to drought conditions in Western and Southwestern states where water allocation has been implemented. During the first half of 2022, customer procurement activity was exceptionally high in the first quarter and then stepped down to a more normalized level in the second quarter.

Cost of sales within the domestic crop business increased 17%, as compared to the first six months of 2021, driven by sales that increased by 29% including increased sales of higher margin products (many of which we manufacture in our domestic facilities) and benefitting from improved factory performance. Gross profit rose by 46% to $70,212 from $48,076.

Our **domestic non-crop business** recorded an 11% decrease in net sales for the first half of the year (to $34,712 from $38,941). This decrease was largely due to a one-time license fee from P&G relating to Envance technology that had been received in the first half of 2021 and was recorded as revenue. Under the terms of that license, depending upon the achievement of commercialization milestones by the licensee, the Company will receive royalties in future reporting periods. Furthermore, in this category, sales of our Dibrom® mosquito adulticide remained flat as did demand for commercial pest control products (pest strips, bifenthrin). Sales of our OHP nursery and ornamental business were comparable to the same period of the prior year, with reduced demand for homeowner garden and landscape products resulting from continually reducing pandemic restrictions, offset by increased demand from professional landscape service providers.

Cost of sales within the domestic non-crop business decreased by 5%, (to $18,698 in 2022 from $19,776 in 2021). Gross profit for domestic non-crop decreased by 16% to $16,014 in 2022 from $19,165 in 2021, due largely to the non-recurrence of a one-time, upfront license fee as described above.

Net sales of our **international businesses** increased by 18% during the first half of 2022 (to $111,419 in 2022 from $94,494 in 2021). Central America experienced double-digit growth in all but one of its six countries. Mexico generated strong results with continuing demand for soil fumigants (on high-value crops), herbicides and granular insecticides. Similarly, Australia enjoyed improved sales driven by improved rainfall and the extended footprint arising from the integration of the AgNova business. Brazil is now on an upward trend, due to a rebound in the agricultural sector and further market penetration of our granular insecticides.

Cost of sales in our international business increased by 19% (to $76,559 in 2022 from $64,465 in 2021) primarily driven by volume growth and impacted by increased prices from the strengthening US Dollar, and general inflation on materials and associated logistics costs. Gross profit for the international businesses increased by 16% to $34,860 in 2022 from $30,029 in 2021.

On a consolidated basis, gross profit for the six months of 2022 increased by 24% (to $120,972 in 2022 from $97,270 in 2021). This is the same rate of growth that we had seen last year, when we compared the first half of 2021 with that of 2020. Our gross profit in the first six months of 2022 increased in part as a result of improved sales volumes and pricing in part due to improved factory performance. Gross margin performance, when expressed as a percentage of sales, rose to 41% from 39% year-over-year.

Operating expenses increased by $10,886 to $95,410 for the six-month period ended June 30, 2022, as compared to the same period in 2021. The differences in operating expenses by department are as follows:

|  | 2022 | 2021 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $23,683 | $22,765 | $918 | 4% |
| General and administrative: |  |  |  |  |
| Other | 34,691 | 31,091 | 3,600 | 12% |
| Proxy contest activities | 1,785 | — | 1,785 | 100% |
| Research, product development and regulatory | 14,728 | 13,545 | 1,183 | 9% |
| Freight, delivery and warehousing | 20,523 | 17,123 | 3,400 | 20% |
|  | $95,410 | $84,524 | 10,886 | 13% |

- Selling expenses increased by $918 to end at $23,683 for the six-month period ended June 30, 2022, as compared to the same period of 2021. The main drivers were increased costs associated with travel expenses (as the business resumed in-person interaction with customers), increased spending on advertising and promoting the Company’s products and movements in some key exchange rates.
- General and administrative expenses increased by $3,600 to end at $34,691 for the six-month period ended June 30, 2022, as compared to the same period of 2021. The main drivers were the adverse impact of the movements in the foreign currency exchange rates, increased incentive compensation as the result of improved performance, increased wages, travel expenses and other administrative costs in support of our growing business.
- The Company spent $1,785 in fees associated with our Proxy defense activities; there were no such fees in the comparative period of the prior year.
- Research, product development costs and regulatory expenses increased by $1,183 to end at $14,728 for the six-month period ended June 30, 2022, as compared to the same period of 2021. The main drivers were increased costs associated with in-field activities in support of our proprietary delivery systems, and our research and product development activities.
- Freight, delivery and warehousing costs for the six-month period ended June 30, 2022 were $20,523 or 6.9% of sales as compared to $17,123 or 6.8% of sales for the same period in 2021. This increased expense is primarily driven by strong sales growth.

During the six-month period ended June 30, 2022, the Company recorded a decrease in the fair value of our equity investment in Clean Seed in the amount of $403 and recorded an increase in the amount of $771 during the six months ended June 30, 2021. These changes in fair value of our investment directly reflect changes in the stock’s quoted market price.

During the six-month period ended June 30, 2021, a Paycheck Protection Program loan assumed on the acquisition of Agrinos in the fourth quarter of 2020 was fully extinguished with the majority of the balance forgiven and recorded as other income in the Company’s condensed consolidated statements of operations in the amount of $672.

Interest costs net of capitalized interest were $1,170 in the first six-month period of 2022, as compared to $1,959 in the same period of 2021. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Six months ended June 30, 2022 Average Debt | Interest Expense | Interest Rate | Six months ended June 30, 2021 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $105,076 | $1,146 | 2.2% | $144,324 | $1,843 | 2.6% |
| Amortization of deferred loan fees | — | 138 | — | — | 161 | — |
| Amortization of other deferred liabilities | — | 17 | — | — | (9) | — |
| Other interest (income) expense | — | 21 | — | — | 89 | — |
| Subtotal | 105,076 | 1,322 | 2.5% | 144,324 | 2,084 | 2.9% |
| Capitalized interest | — | (152) | — | — | (125) | — |
| Total | $105,076 | $1,170 | 2.2% | $144,324 | $1,959 | 2.7% |

The Company’s average overall debt for the six-month period ended June 30, 2022, was $105,076, as compared to $144,324 for the six months ended June 30, 2021. During the period, we continued to focus on our use of revolving debt, while funding working capital for the growing business. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.2% for the six months ended June 30, 2022, as compared to 2.6% in 2021.

Income tax expense increased by $3,417 to end at $7,224 for the six-month period ended June 30, 2022, as compared to income tax expense of $3,807 for the comparable period in 2021. The effective tax rate for the six months ended June 30, 2022, was 30.1% as compared to 31.4% for same period last year. The rate has decreased compared to prior year reflecting a mix of income in different jurisdictions and an increased benefit from the vesting of certain stock grants. For tax years beginning after December 31, 2021, the Tax Cuts and Jobs Act (“TCJA”) of 2017 amends Internal Revenue Code Section 174 costs wherein research and development expenditures will no longer be deducted in the tax year that such costs are incurred but must now be capitalized and amortized over either a five- or fifteen-year period, depending on the location of the activities performed. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Our net income for the six-month period ended June 30, 2022 was $16,765 or $0.57 per basic and $0.55 per diluted share, as compared to $8,215 or $0.28 per basic and $0.27 per diluted share in the same period of 2021.

### LIQUIDITY AND CAPITAL RESOURCES

The Company’s operating activities utilized net cash of $27,230 during the six-month period ended June 30, 2022, as compared to $18,905 during the six months ended June 30, 2021. Included in the $27,230 are net income of $16,765, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $12,760, loss on disposal of property, plant and equipment of $256, amortization of deferred loan fees of $139 and provision for bad debts in the amount of $470. Also included are stock-based compensation of $2,836, adjustment to contingent consideration in the amount of $635, increase in deferred income taxes of $109, change in fair value of an equity investment of $403, and net foreign currency adjustments of $20. These together provided net cash inflows of $34,353, as compared to $24,930 for the same period of 2021.

During the six-month period of 2022, the Company increased working capital by $68,187, as compared to an increase of $43,715 during the same period of the prior year. Included in this change: inventories increased by $27,774, as compared to $11,464 for the same period of 2021. While increases in inventory are normal for the Company’s annual cycle, this year, the Company has made decisions to bring in raw materials earlier than in prior seasons in order to secure our needs of key materials for the balance of the year and the start of the next growing season.

Customer prepayments decreased by $62,789, as compared to $30,407 in the same period of 2021, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $19,439, as compared to an increase of $6,190 in the same period of 2021, driven by increased factory activity levels. Accounts receivables increased by $18,645, as compared to an increase of $25,317 in the same period of 2021. This is primarily driven by increased group sales and strong international growth. Prepaid expenses increased by $3,652, as compared to $3,696 in the same period of 2021. Income tax receivable increased by $3,526, as compared to a decrease of $1,374 in the prior year. Accrued programs increased by $35,987, as compared to $19,098 in the prior year, which is normal at this point in the growing season. Finally, other payables and accrued expenses decreased by $602, as compared to an increase of $507 in the prior year.

With regard to our program accrual, the increase (as noted above) primarily reflects our volume and mix of sales (certain products are marketed with higher levels of program accruals), and customers in the first six months of 2022, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first six months of 2022, the Company made accruals for programs in the amount of $67,274 and payments in the amount of $31,367. During the first six months of the prior year, the Company made accruals in the amount of $39,235 and made payments in the amount of $20,142. The increase in accruals for programs in the first six months of 2022, compared to the same period in 2021, is a direct result of an increase in sales of qualifying products.

Cash used for investing activities for the six-month period ended June 30, 2022, and 2021 was $6,671 and $15,500, respectively. The $15,500 in 2021 includes a product acquisition in the amount of $10,000. No such acquisition took place in the current year. In 2022, the Company spent $5,654 on purchases of fixed assets primarily focused on continuing to invest in manufacturing infrastructure. In addition, the Company made a payment of $1,000 to Clean Seed to amend a license agreement under which royalty-bearing license rights were converted to fully paid-up, royalty-free, perpetual license rights, and spent $44 on patents for the Envance technology business.

During the six-month period ended June 30, 2022, financing activities provided $40,027, as compared to $37,943 during the same period of the prior year. Net borrowings under the Credit Agreement amounted to $48,400 during the six-month period ended June 30, 2022, as compared to $41,774 in the same period of the prior year. The Company paid dividends to stockholders amounting to $1,330 during the six months ended June 30, 2022, as compared to $1,188 in the same period of 2021. The Company paid $6,232 for the repurchase of 333,010 shares of its common stock during the six-month period ended June 30, 2022. There were no such purchases during the six-month period ended June 30, 2021. Lastly, in exchange for shares of common stock returned by employees, the Company paid $2,012 and $2,900 for tax withholding on stock-based compensation awards during the six months ended June 30, 2022 and 2021, respectively.

The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021. These are summarized in the following table:

| Long-term indebtedness ($000's) | June 30, 2022 | December 31, 2021 |
| --- | ---: | ---: |
| Revolving line of credit | $101,700 | $53,300 |
| Deferred loan fees | (921) | (1,060) |
| Net long-term debt | $100,779 | $52,240 |

At June 30, 2022, the Company was compliant with all covenants to its credit agreement. Also, at June 30, 2022, the Company’s total Funded Debt amounted to $101,700. At that date the Company’s rolling four quarter Consolidated EBITDA (as defined in the Credit Agreement, see Note 10) amounted to $75,512, which results in a leverage ratio of 1.35, as compared to a maximum leverage ratio permitted under the Credit Agreement of 3.5. At June 30, 2022, the Company has the capacity to increase its borrowings by up to $162,592, according to the terms thereof. This compares to an available borrowing capacity of $56,906 as of June 30, 2021. At December 31, 2021, the Company had borrowing capacity of $178,705. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve-month period and proforma basis arising from acquisitions, (2) net borrowings, and (3) the leverage covenant (the TL Ratio).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our amended senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 15 in the accompanying Notes to the condensed consolidated financial statements for recently issued accounting standards.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2021, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2021.

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions. Our estimates did not change materially during the three- and six-months ended June 30, 2022.

## Market risk

As filed, 1,236 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2021 and note 10 to the condensed consolidated financial statements.

The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.

Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe, Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.

## Controls and procedures

As filed, 1,056 characters.

As of June 30, 2022, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2022, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 4,651 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 14, 2022. The following disclosure amends and supplements those risk factors and, except to the extent restated below, there are no material changes to the risk factors as so stated.

***An NGO petition to revoke tolerances a family of chemistries (namely, organophosphate) could jeopardize several of the Company’s products.*** *O*n November 18, 2021, a group of non-governmental organizations led by Pesticide Action Network North America filed a petition with the USEPA to revoke the food tolerances for eight of the Company’s registered active ingredients, all of which are in the family of organophosphates. In July 2022, USEPA published in the Federal Register an invitation for public comment on the petition, giving commenters 30 days’ within which to submit their comments. In light of the large number of active ingredients implicated by the petition, the Company and multiple other stakeholders (including grower groups and trade organizations) are seeking an extension of time for submitting such comments. While the Company does not believe that there is a valid basis for revoking tolerances under applicable law (as the petition is largely based upon unsound studies solely involving chlorypyrifos), there is no guarantee that USEPA will grant an extension or, for that matter, will deny the remedy being sought by the petition. It is possible that USEPA could find a basis upon which to revoke tolerances and therefore cancel one or all active ingredients which, in turn, could have a material adverse effect upon the Company’s financial performance. Further, this matter is unprecedented insofar as it, in effect, targets an entire class of chemistry (as opposed to one active ingredient); thus, it is possible that, if granted, this petition will establish an adverse precedent by which NGOs can seek to cancel other families of chemistries within the broader industry.

***USEPA’s notice of intention to suspend the DCPA registration could have a broader impact on the Company’s portfolio and the industry in general.*** In May 2022, the USEPA issued a notice of intention to suspend DCPA, the active ingredient of an herbicidal product marketed by the Company under the name Dacthal on the basis that the Company acted allegedly inappropriately in providing data studies that had been requested by the agency. In fact, the agency had requested 89 data studies and, over the course of several years, the Company had supplied 69 such studies and had been working constructively on mutually acceptable timetables either to complete, or to obtain waivers for, the balance of the studies. The Company petitioned an administrative law judge (“ALJ”) to appeal the NOITS. In response to USEPA’s motion, the ALJ granted an accelerated decision to uphold the NOITS. The Company, in turn, has appealed the ALJ’s decision to the Environmental Appeals Board, on the ground that the basis was erroneous, both with respect to statutory construction and factual inferences being improperly made in the agency’s favor. While the Company believes that there is no merit to the agency’s position, there is no guarantee that the Company will prevail in defending against the attempted suspension. Further, if this suspension is granted, it is possible that the agency will seek to invalidate registrations summarily, including both the Company’s and those of its peers. This, in turn, could have a material adverse effect upon the Company’s financial performance.

***The Catalano product liability case could set an adverse precedent for the active ingredient acephate, as well as for organophosphates more generally.*** As more fully described in Part 14, Item II herein, plaintiffs in Catalano seek damages for cardiovascular injury allegedly arising from making applications of Orthene, a systemic insecticide marketed by the Company, having acephate as its active ingredient. While the Company believes that the claim has not merit and that there have been no data studies linking acephate to cardiovascular disease, it is possible that a court could reach a judgment that is adverse to the Company and, in so doing, set an adverse precedent with respect not only to commercial acephate products, but also to consumer acephate products and organophosphate products more generally. Such adverse judgment and/or precedent could have a materially adverse effect upon the Company’s financial performance.

Filed Aug 8, 2022.
Source: SEC EDGAR, the filing index for accession 0001564590-22-028438. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
